JP2019513836A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513836A5
JP2019513836A5 JP2019503903A JP2019503903A JP2019513836A5 JP 2019513836 A5 JP2019513836 A5 JP 2019513836A5 JP 2019503903 A JP2019503903 A JP 2019503903A JP 2019503903 A JP2019503903 A JP 2019503903A JP 2019513836 A5 JP2019513836 A5 JP 2019513836A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
fragment
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025951 external-priority patent/WO2017176760A2/en
Publication of JP2019513836A publication Critical patent/JP2019513836A/ja
Publication of JP2019513836A5 publication Critical patent/JP2019513836A5/ja
Pending legal-status Critical Current

Links

JP2019503903A 2016-04-04 2017-04-04 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法 Pending JP2019513836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317906P 2016-04-04 2016-04-04
US62/317,906 2016-04-04
PCT/US2017/025951 WO2017176760A2 (en) 2016-04-04 2017-04-04 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Publications (2)

Publication Number Publication Date
JP2019513836A JP2019513836A (ja) 2019-05-30
JP2019513836A5 true JP2019513836A5 (https=) 2020-05-14

Family

ID=60001426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503903A Pending JP2019513836A (ja) 2016-04-04 2017-04-04 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法

Country Status (6)

Country Link
US (2) US11021536B2 (https=)
EP (1) EP3439699A4 (https=)
JP (1) JP2019513836A (https=)
CN (1) CN109562164B (https=)
CA (1) CA3019581A1 (https=)
WO (1) WO2017176760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP3623383A1 (en) * 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
CN113056486B (zh) 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
JP7642542B2 (ja) 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
WO2021007266A1 (en) * 2019-07-09 2021-01-14 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
WO2023023491A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
WO2016172026A1 (en) 2015-04-20 2016-10-27 The Board Of Regents Of The University Of Texas System Clec11a is a bone growth agent
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
EP3612568B8 (en) 2017-04-18 2021-12-08 Autolus Limited Cell

Similar Documents

Publication Publication Date Title
JP2019513836A5 (https=)
JP6964631B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
CN109535257B (zh) 新型双特异性cd3/cd19多肽复合物
CN104105708B (zh) PDGF受体β结合多肽
JP2021530236A5 (https=)
JP2022519082A (ja) 新規ｃｄ４０結合抗体
JP2018505674A5 (https=)
JP2017529067A (ja) Ｃｄ３結合ドメイン
US20240392008A1 (en) Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
JPWO2019175223A5 (https=)
CN107428832A (zh) 抗pd‑l1抗体
CN106243225B (zh) 新型抗-pd-l1抗体
WO2022200525A1 (en) Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
CN115093481A (zh) 新型双特异性cd3/cd20多肽复合物
CN117529504A (zh) 结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
JP2019512207A5 (https=)
JPWO2020018852A5 (https=)
JP2023538117A (ja) 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
JP2021511387A5 (https=)
WO2019206095A1 (zh) 针对tim-3的抗体及其用途
JP7825834B2 (ja) 抗ｃ４ｄキメラ抗原受容体調節性ｔ細胞およびその使用
WO2022258691A1 (en) Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
JP2022500455A5 (https=)